Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies
about
Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma TherapyCurrent and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells.Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumabTherapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond.Emerging immunological drugs for chronic lymphocytic leukemia.Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R.A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages via the Fc domain, resulting in cell death by phagoptosis.Loss of Immune Tolerance Is Controlled by ICOS in Sle1 Mice.Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cellsPyrosequencing for classification of human FcγRIIIA allotypes: a comparison with PCR-based techniques.Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia.
P2860
Q26775363-78155694-E66D-4317-ACD8-B47DD8F2BF96Q34440110-AE303D74-A3EF-4219-A305-88E9B8008D0FQ36870059-0FD00E44-F943-413C-AACF-88B4343F4953Q37022365-B50FC52E-2394-4252-BB20-DEAE4CD7002DQ38124065-1394DEAF-06EA-41BB-95DD-D0803B1FC941Q38543771-95B44307-F438-4C4D-9F0B-C11BD0AF2A13Q38759754-2FFE59AA-80A4-4182-B69D-0E04E4440AC8Q38995180-C0650486-9157-418D-B789-BD3AD884D034Q39004366-3290EFC5-D4FB-46B5-AD8D-6E075AEA122DQ42057546-9322A4BC-C455-408D-8341-607E5AAF2826Q42149294-5A6F2582-13E8-4241-82C6-A593C824267FQ42556477-DE40A4AB-F4F0-4D74-8416-A5B3570A623AQ53019116-CDF0BDF8-099F-4947-AD84-F37D9A3631BAQ53758334-56996006-756A-4015-B4C3-60407BEB5F5C
P2860
Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Macrophage and NK-mediated kil ...... anti-CD19 humanized antibodies
@ast
Macrophage and NK-mediated kil ...... anti-CD19 humanized antibodies
@en
Macrophage and NK-mediated kil ...... anti-CD19 humanized antibodies
@nl
type
label
Macrophage and NK-mediated kil ...... anti-CD19 humanized antibodies
@ast
Macrophage and NK-mediated kil ...... anti-CD19 humanized antibodies
@en
Macrophage and NK-mediated kil ...... anti-CD19 humanized antibodies
@nl
prefLabel
Macrophage and NK-mediated kil ...... anti-CD19 humanized antibodies
@ast
Macrophage and NK-mediated kil ...... anti-CD19 humanized antibodies
@en
Macrophage and NK-mediated kil ...... anti-CD19 humanized antibodies
@nl
P2093
P2860
P921
P356
P1433
P1476
Macrophage and NK-mediated kil ...... anti-CD19 humanized antibodies
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2013.5
P577
2013-01-11T00:00:00Z
P5875
P6179
1001187008